Uzbekistan and Tajikistan explore joint pharmaceutical production
Uzbekistan and Tajikistan are exploring closer collaboration in the pharmaceutical sector, with an emphasis on joint manufacturing, domestic production of medicines and medical devices, increased exports, and new investment ventures. These topics were central to discussions at a recent Uzbekistan–Tajikistan pharmaceutical business forum, which saw participation from government officials and industry leaders from both nations.
Attendees at the forum included representatives from Tajikistan’s Ministry of Health and Social Protection of the Population, its State Supervision Service, the Sughd regional department, and the state enterprise responsible for evaluating pharmaceutical and medical products, alongside pharmaceutical companies from both Uzbekistan and Tajikistan.
During a meeting, Abdulla Azizov, Director of Uzbekistan’s Agency for the Development of the Medical and Pharmaceutical Industry, and a Tajik delegation headed by First Deputy Minister of Health and Social Protection of the Population Yusuf Salomuddin, assessed the current state of their respective pharmaceutical industries, identified existing opportunities, and pinpointed potential areas for partnership.
Key areas of focus included establishing manufacturing partnerships, localizing the production of medicines and medical equipment, boosting export volumes, and executing collaborative projects. The Tajik delegation also toured Uzbekistan’s BioPharma City pharmaceutical cluster, where they learned about ongoing initiatives, advanced production facilities, infrastructure, and localization prospects. Additionally, the delegation received details regarding the construction and academic programs of the Pharmaceutical Technical University.
Business-to-business (B2B) meetings facilitated discussions between Uzbek pharmaceutical manufacturers and Tajik companies. These conversations addressed proposals for market entry into Tajikistan, expanding bilateral trade, technology transfer, and establishing joint production facilities. Participants were also shown medicines and medical equipment produced domestically in Uzbekistan.
The forum concluded with a commitment to maintain practical dialogue aimed at broadening mutually beneficial pharmaceutical cooperation, fostering direct relationships between manufacturers, and implementing promising joint projects.
Previous reports highlight significant growth in Uzbekistan’s pharmaceutical market. According to IQVIA, the wholesale market reached $204.9 million in September 2025, with 83.1 million medicine packages sold. This represents a year-on-year increase of 36.4% in value and 24.1% in volume. Over the 12 months leading up to September 2025, the market's annual volume was estimated at $2.14 billion, a substantial rise from approximately $888 million in 2018.